Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration.
Robert A RosenheckSonia T AnandStephen G KurtzCynthia HauDiane SmedbergJames F PontzerRyan E FergusonCynthia R DavisPublished in: Trials (2023)
The declining use of LAI risperidone likely primarily reflects the substitution of a longer-acting LAI SGA, paliperidone, that came to market 2 years before the study publication, a substitution that may have been reinforced by null CSP#555 study results for LAI risperidone.